Thermo Fisher

Thermo Fisher Scientific's Q1 Earnings Preview: Analysts Expect 3.1% EPS Growth

Thermo Fisher Scientific: Assessing Valuation After SHL Medical Alliance and US Capacity Expansion

Thermo Fisher and SHL Medical Collaborate on Integrated Drug-Device Solutions

Thermo Fisher Scientific Acquires Clario Holdings for $8.875 Billion, Boosting Conservative Stock Portfolio

赛默飞世尔

Thermo Fisher's 15min chart triggers MACD Death Cross, KDJ Death Cross alert.

Catalyst<ul> <li>Most analysts rate TMO Buy or Strong Buy, showing broad institutional optimism.</li></ul>Risk<ul> <li>Technical indicators show that the market is in a volatile state and the direction is not clear enough.</li> <li>Bearish signals are obviously dominant (2 bearish vs 0 bullish).</li> <li>Fund flow overall trend is negative with large and extra-large orders showing outflows.</li></ul>

Key Factors

Thermo Fisher (TMO) fell over 3.1% in early trading hitting an intraday low of $472.41 near a 6-month trough. Analysts expect TMO's Q1 2026 earnings to show 3.1% year-over-year EPS growth to $5.31 per share. TMO's fair value is estimated at $540.27 despite a 17.5% YTD share price decline driven by R&D budget concerns and integration risks.

TMO News